Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CRIZANLIZUMAB-TMCA Cause Product temperature excursion issue? 15 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Product temperature excursion issue have been filed in association with CRIZANLIZUMAB-TMCA. This represents 1.3% of all adverse event reports for CRIZANLIZUMAB-TMCA.

15
Reports of Product temperature excursion issue with CRIZANLIZUMAB-TMCA
1.3%
of all CRIZANLIZUMAB-TMCA reports
0
Deaths
0
Hospitalizations

How Dangerous Is Product temperature excursion issue From CRIZANLIZUMAB-TMCA?

Of the 15 reports.

Is Product temperature excursion issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CRIZANLIZUMAB-TMCA. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does CRIZANLIZUMAB-TMCA Cause?

Pain (313) Sickle cell anaemia with crisis (263) Back pain (125) Infusion related reaction (110) Arthralgia (81) Pain in extremity (75) Drug ineffective (74) Chest pain (63) Pyrexia (62) Nausea (57)

What Other Drugs Cause Product temperature excursion issue?

SECUKINUMAB (219) ADALIMUMAB (190) ABATACEPT (158) OFATUMUMAB (157) INSULIN GLARGINE (130) TOCILIZUMAB (129) VEDOLIZUMAB (111) ONABOTULINUMTOXINA (96) BRENTUXIMAB VEDOTIN (94) RISANKIZUMAB (88)

Which CRIZANLIZUMAB-TMCA Alternatives Have Lower Product temperature excursion issue Risk?

CRIZANLIZUMAB-TMCA vs CRIZOTINIB CRIZANLIZUMAB-TMCA vs CROFELEMER CRIZANLIZUMAB-TMCA vs CROMOLYN CRIZANLIZUMAB-TMCA vs CROTALIDAE POLYVALENT IMMUNE FAB CRIZANLIZUMAB-TMCA vs CUBICIN

Related Pages

CRIZANLIZUMAB-TMCA Full Profile All Product temperature excursion issue Reports All Drugs Causing Product temperature excursion issue CRIZANLIZUMAB-TMCA Demographics